Clinical trial conducted in the NC TraCS CTRC leads to first FDA-approved medication for eosinophilic esophagitis

Previously, treating patients with eosinophilic esophagitis (EoE) in the U.S. meant relying on potentially less effective approaches or off-label medications as there were no FDA-approved medications to treat EoE.

To address this gap and improve patient outcomes, Evan Dellon, MD, MPH, a professor of medicine at the UNC School of Medicine, worked with colleagues on a clinical trial conducted in the NC TraCS Clinical and Translational Research Center (CTRC) that led to the first FDA-approved medication for treatment of EoE in adults and adolescents.